Tauroursodeoxycholic Acid Improves Motor Symptoms in a Mouse Model of Parkinson’s Disease

Molecular Neurobiology

Volumn 55, Issue 12, 2018, Pages 9139-9155

  Rosa, Alexandra Isabel ^a   Duarte Silva, Sara ^b,c   Silva Fernandes, Anabela ^b,c   Nunes, Maria João ^a   Carvalho, Andreia Neves ^a   Rodrigues, Elsa ^a,d   Gama, Maria João ^a,d   Rodrigues, Cecília Maria Pereira ^a,d   Maciel, Patrícia ^b,c   Castro Caldas, Margarida ^a,e  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c UNIVERSITY OF MINHO   (Portugal)

^d UNIVERSITY OF LISBON   (Portugal)

^e UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

Behavioral tests; MPTP; Neuroinflammation; Parkinson s disease; TUDCA

Indexed keywords

ADENOSINE TRIPHOSPHATE; TAUROURSODEOXYCHOLIC ACID; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; NEUROPROTECTIVE AGENT; TAUROCHENODEOXYCHOLIC ACID;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIORAL SCIENCE; CELL VIABILITY; CLINICAL FEATURE; CLINICAL PROTOCOL; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; GAIT; HUMIDITY; IMMUNOHISTOCHEMISTRY; LATENT PERIOD; MALE; MOTOR COORDINATION; MOTOR PERFORMANCE; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PROTEIN BLOOD LEVEL; ROTAROD TEST; SWIMMING; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; GLIA; HINDLIMB; HOMEOSTASIS; INFLAMMATION; METABOLISM; MITOCHONDRION; MOTOR ACTIVITY; MOVEMENT (PHYSIOLOGY); NEOSTRIATUM; NERVE DEGENERATION; PATHOLOGY; PATHOPHYSIOLOGY; TREMOR;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; DISEASE MODELS, ANIMAL; GAIT; HINDLIMB; HOMEOSTASIS; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MITOCHONDRIA; MOTOR ACTIVITY; MOVEMENT; NEOSTRIATUM; NERVE DEGENERATION; NEUROGLIA; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; TAUROCHENODEOXYCHOLIC ACID; TREMOR;

EID: 85045271175     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-018-1062-4     Document Type: Article

References (66)

1. Hald A, Lotharius J (2005) Oxidative stress and inflammation in Parkinson’s disease: is there a causal link? Exp Neurol 193(2):279–290. 10.1016/j.expneurol.2005.01.013
2. Vila M, Ramonet D, Perier C (2008) Mitochondrial alterations in Parkinson’s disease: new clues. J Neurochem 107(2):317–328. 10.1111/j.1471-4159.2008.05604.x
3. Sofroniew MV, Vinters HV (2010) Astrocytes: biology and pathology. Acta Neuropathol 119(1):7–35. 10.1007/s00401-009-0619-8
4. Choi SS, Lee HJ, Lim I, Satoh J, Kim SU (2014) Human astrocytes: secretome profiles of cytokines and chemokines. PLoS One 9(4):e92325. 10.1371/journal.pone.0092325
5. Morizawa YM, Hirayama Y, Ohno N, Shibata S, Shigetomi E, Sui Y, Nabekura J, Sato K et al (2017) Reactive astrocytes function as phagocytes after brain ischemia via ABCA1-mediated pathway. Nat Commun 8(1):28. 10.1038/s41467-017-00037-1
6. Hirsch EC, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel PP (2003) The role of glial reaction and inflammation in Parkinson’s disease. Ann N Y Acad Sci 991:214–228
7. Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P (1995) Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer’s and de novo Parkinson’s disease patients. Neurosci Lett 202(1–2):17–20
8. Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, Munch AE et al (2017) Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541(7638):481–487. 10.1038/nature21029
9. McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38(8):1285–1291
10. Miklossy J, Doudet DD, Schwab C, Yu S, McGeer EG, McGeer PL (2006) Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp Neurol 197(2):275–283. 10.1016/j.expneurol.2005.10.034
11. Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T (1994) Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 180(2):147–150
12. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T (1994) Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165(1–2):208–210
13. Muller T, Blum-Degen D, Przuntek H, Kuhn W (1998) Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson’s disease. Acta Neurol Scand 98(2):142–144
14. Blin O, Desnuelle C, Rascol O, Borg M, Peyro Saint Paul H, Azulay JP, Bille F, Figarella D et al (1994) Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson’s disease and multiple system atrophy. J Neurol Sci 125(1):95–101
15. Mann VM, Cooper JM, Krige D, Daniel SE, Schapira AH, Marsden CD (1992) Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson’s disease. Brain 115(Pt 2):333–342
16. Yoshino H, Nakagawa-Hattori Y, Kondo T, Mizuno Y (1992) Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson’s disease. J Neural Transm Park Dis Dement Sect 4(1):27–34
17. Chun HS, Gibson GE, DeGiorgio LA, Zhang H, Kidd VJ, Son JH (2001) Dopaminergic cell death induced by MPP(+), oxidant and specific neurotoxicants shares the common molecular mechanism. J Neurochem 76(4):1010–1021
18. Nicotra A, Parvez S (2002) Apoptotic molecules and MPTP-induced cell death. Neurotoxicol Teratol 24(5):599–605
19. Przedborski S, Vila M (2003) The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson’s disease. Ann N Y Acad Sci 991:189–198
20. Heng Y, Zhang QS, Mu Z, Hu JF, Yuan YH, Chen NH (2016) Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting alpha-synuclein abnormalities in the substantia nigra. Toxicol Lett 243:7–21. 10.1016/j.toxlet.2015.12.005
21. Thomas B, Beal MF (2007) Parkinson’s disease. Hum Mol Genet 16(Spec 2):R183–R194. 10.1093/hmg/ddm159
22. Martin I, Dawson VL, Dawson TM (2011) Recent advances in the genetics of Parkinson’s disease. Annu Rev Genomics Hum Genet 12:301–325. 10.1146/annurev-genom-082410-101440
23. Klein C, Westenberger A (2012) Genetics of Parkinson’s disease. Cold Spring Harb Perspect Med 2(1):a008888. 10.1101/cshperspect.a008888
24. Dawson TM, Dawson VL (2014) Parkin plays a role in sporadic Parkinson’s disease. Neurodegener Dis 13(2–3):69–71. 10.1159/000354307
25. West AB, Maidment NT (2004) Genetics of parkin-linked disease. Hum Genet 114(4):327–336. 10.1007/s00439-003-1074-6
26. Shin JH, Ko HS, Kang H, Lee Y, Lee YI, Pletinkova O, Troconso JC, Dawson VL et al (2011) PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson’s disease. Cell 144(5):689–702. 10.1016/j.cell.2011.02.010
27. Duplan E, Giaime E, Viotti J, Sevalle J, Corti O, Brice A, Ariga H, Qi L et al (2013) ER-stress-associated functional link between Parkin and DJ-1 via a transcriptional cascade involving the tumor suppressor p53 and the spliced X-box binding protein XBP-1. J Cell Sci 126(Pt 9):2124–2133. 10.1242/jcs.127340
28. Marsden CD (1994) Problems with long-term levodopa therapy for Parkinson’s disease. Clin Neuropharmacol 17(Suppl 2):S32–S44
29. Keene CD, Rodrigues CM, Eich T, Chhabra MS, Steer CJ, Low WC (2002) Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington’s disease. Proc Natl Acad Sci U S A 99(16):10671–10676. 10.1073/pnas.162362299
30. Nunes AF, Amaral JD, Lo AC, Fonseca MB, Viana RJ, Callaerts-Vegh Z, D'Hooge R, Rodrigues CM (2012) TUDCA, a bile acid, attenuates amyloid precursor protein processing and amyloid-beta deposition in APP/PS1 mice. Mol Neurobiol 45(3):440–454. 10.1007/s12035-012-8256-y
31. Rodrigues CM, Stieers CL, Keene CD, Ma X, Kren BT, Low WC, Steer CJ (2000) Tauroursodeoxycholic acid partially prevents apoptosis induced by 3-nitropropionic acid: evidence for a mitochondrial pathway independent of the permeability transition. J Neurochem 75(6):2368–2379
32. Ved R, Saha S, Westlund B, Perier C, Burnam L, Sluder A, Hoener M, Rodrigues CM et al (2005) Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. J Biol Chem 280(52):42655–42668. 10.1074/jbc.M505910200
33. Castro-Caldas M, Carvalho AN, Rodrigues E, Henderson CJ, Wolf CR, Rodrigues CM, Gama MJ (2012) Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson’s disease. Mol Neurobiol 46(2):475–486. 10.1007/s12035-012-8295-4
34. Moreira S, Fonseca I, Nunes MJ, Rosa A, Lemos L, Rodrigues E, Carvalho AN, Outeiro TF et al (2017) Nrf2 activation by tauroursodeoxycholic acid in experimental models of Parkinson’s disease. Exp Neurol 295:77–87. 10.1016/j.expneurol.2017.05.009
35. Rosa AI, Fonseca I, Nunes MJ, Moreira S, Rodrigues E, Carvalho AN, Rodrigues CMP, Gama MJ et al (2017) Novel insights into the antioxidant role of tauroursodeoxycholic acid in experimental models of Parkinson’s disease. Biochim Biophys Acta 1863:2171–2181. 10.1016/j.bbadis.2017.06.004
36. Cunha MP, Pazini FL, Lieberknecht V, Budni J, Oliveira A, Rosa JM, Mancini G, Mazzardo L et al (2016) MPP+-lesioned mice: an experimental model of motor, emotional, memory/learning, and striatal neurochemical dysfunctions. Mol Neurobiol 54:6356–6377. 10.1007/s12035-016-0147-1
37. Rozas G, Lopez-Martin E, Guerra MJ, Labandeira-Garcia JL (1998) The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. J Neurosci Methods 83(2):165–175
38. Sedelis M, Hofele K, Auburger GW, Morgan S, Huston JP, Schwarting RK (2000) MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet 30(3):171–182
39. Guillen J (2012) FELASA guidelines and recommendations. J Am Assoc Lab Anim Sci 51(3):311–321
40. Nicklas W, Baneux P, Boot R, Decelle T, Deeny AA, Fumanelli M, Illgen-Wilcke B, Felasa (2002) Recommendations for the health monitoring of rodent and rabbit colonies in breeding and experimental units. Lab Anim 36 (1):20–42. doi:10.1258/0023677021911740
41. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S (1995) Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4(3):257–269
42. Jackson-Lewis V, Przedborski S (2007) Protocol for the MPTP mouse model of Parkinson’s disease. Nat Protoc 2(1):141–151. 10.1038/nprot.2006.342
43. Saporito MS, Thomas BA, Scott RW (2000) MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo. J Neurochem 75(3):1200–1208
44. Crosignani A, Setchell KD, Invernizzi P, Larghi A, Rodrigues CM, Podda M (1996) Clinical pharmacokinetics of therapeutic bile acids. Clin Pharmacokinet 30(5):333–358
45. Castro-Caldas M, Neves Carvalho A, Peixeiro I, Rodrigues E, Lechner MC, Gama MJ (2009) GSTpi expression in MPTP-induced dopaminergic neurodegeneration of C57BL/6 mouse midbrain and striatum. J Mol Neurosci 38(2):114–127. 10.1007/s12031-008-9141-z
46. Keene CD, Rodrigues CM, Eich T, Linehan-Stieers C, Abt A, Kren BT, Steer CJ, Low WC (2001) A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington’s disease. Exp Neurol 171(2):351–360. 10.1006/exnr.2001.7755
47. Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP, Dunnett SB, Morton AJ (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington’s disease mutation. J Neurosci 19(8):3248–3257
48. Silva-Fernandes A, Duarte-Silva S, Neves-Carvalho A, Amorim M, Soares-Cunha C, Oliveira P, Thirstrup K, Teixeira-Castro A et al (2014) Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado-Joseph disease. Neurotherapeutics 11(2):433–449. 10.1007/s13311-013-0255-9
49. Rogers DC, Fisher EM, Brown SD, Peters J, Hunter AJ, Martin JE (1997) Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment. Mamm Genome 8(10):711–713
50. Teixeira-Castro A, Jalles A, Esteves S, Kang S, da Silva Santos L, Silva-Fernandes A, Neto MF, Brielmann RM et al (2015) Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease. Brain 138(Pt 11):3221–3237. 10.1093/brain/awv262
51. Jankovic J (2008) Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79(4):368–376. 10.1136/jnnp.2007.131045
52. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y et al (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87(3):493–506
53. Hebert G, Arsaut J, Dantzer R, Demotes-Mainard J (2003) Time-course of the expression of inflammatory cytokines and matrix metalloproteinases in the striatum and mesencephalon of mice injected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a dopaminergic neurotoxin. Neurosci Lett 349(3):191–195
54. Pattarini R, Smeyne RJ, Morgan JI (2007) Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson’s disease. Neuroscience 145(2):654–668. 10.1016/j.neuroscience.2006.12.030
55. Vijitruth R, Liu M, Choi DY, Nguyen XV, Hunter RL, Bing G (2006) Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson’s disease. J Neuroinflammation 3:6. 10.1186/1742-2094-3-6
56. Zhang Z, Huang L, Zhao W, Rigas B (2010) Annexin 1 induced by anti-inflammatory drugs binds to NF-kappaB and inhibits its activation: anticancer effects in vitro and in vivo. Cancer Res 70(6):2379–2388. 10.1158/0008-5472.CAN-09-4204
57. Schwarting RK, Sedelis M, Hofele K, Auburger GW, Huston JP (1999) Strain-dependent recovery of open-field behavior and striatal dopamine deficiency in the mouse MPTP model of Parkinson’s disease. Neurotox Res 1(1):41–56
58. Alexander GM, Schwartzman RJ, Grothusen JR, Brainard L, Gordon SW (1993) Changes in brain dopamine receptors in MPTP parkinsonian monkeys following L-dopa treatment. Brain Res 625(2):276–282
59. Fernagut PO, Diguet E, Bioulac B, Tison F (2004) MPTP potentiates 3-nitropropionic acid-induced striatal damage in mice: reference to striatonigral degeneration. Exp Neurol 185(1):47–62
60. Chakraborty J, Basso V, Ziviani E (2017) Post translational modification of Parkin. Biol Direct 12(1):6. 10.1186/s13062-017-0176-3
61. Xiong H, Wang D, Chen L, Choo YS, Ma H, Tang C, Xia K, Jiang W et al (2009) Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. J Clin Invest 119(3):650–660. 10.1172/JCI37617
62. Hong J, Sha S, Zhou L, Wang C, Yin J, Chen L (2015) Sigma-1 receptor deficiency reduces MPTP-induced parkinsonism and death of dopaminergic neurons. Cell Death Dis 6:e1832. 10.1038/cddis.2015.194
63. Feng ZH, Wang TG, Li DD, Fung P, Wilson BC, Liu B, Ali SF, Langenbach R et al (2002) Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra. Neurosci Lett 329(3):354–358
64. Yanguas-Casas N, Barreda-Manso MA, Nieto-Sampedro M, Romero-Ramirez L (2017) TUDCA: an agonist of the bile acid receptor GPBAR1/TGR5 with anti-inflammatory effects in microglial cells. J Cell Physiol 232(8):2231–2245. 10.1002/jcp.25742
65. Yanguas-Casas N, Barreda-Manso MA, Perez-Rial S, Nieto-Sampedro M, Romero-Ramirez L (2016) TGFbeta contributes to the anti-inflammatory effects of tauroursodeoxycholic acid on an animal model of acute neuroinflammation. Mol Neurobiol 54:6737–6749. 10.1007/s12035-016-0142-6
66. Kiani-Esfahani A, Kazemi Sheykhshabani S, Peymani M, Hashemi MS, Ghaedi K, Nasr-Esfahani MH (2016) Overexpression of annexin A1 suppresses pro-inflammatory factors in PC12 cells induced by 1-methyl-4-phenylpyridinium. Cell J 18(2):197–204